Protara Therapeutics Enters 2026 With Advancing TARA-002 Programs, Registrational Trials And Extended Cash Runway Into 2028
Benzinga Newsdesk 9 months ago
News
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs;
- On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026
- Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026
- Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026
- Recently completed approximately $86 million public offering extending cash runway into 2028